Fig. 5From: Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United StatesICER scatter plot US model. GDP = gross domestic product per capita; LY = life year; QALY = quality-adjusted life year. Only the first 1000 iterations were plotted for clarityBack to article page